Prevention of hepatitis C recurrence after liver transplantation: An update

Marco Carbone, Ilaria Lenci, Leonardo Baiocchi

Abstract

Hepatitis C related liver failure and hepatocarcinoma are the most common indications for liver transplantation in Western countries. Recurrent hepatitis C infection of the allograft is universal and immediate following liver transplantation, being associated with accelerated progression to cirrhosis, graft loss and death. Graft and patient survival is reduced in liver transplant recipients with recurrent Hepatitis C virus (HCV) infection compared to HCV-negative recipients. Many variables may impact on recurrent HCV liver disease. Overall, excess immunosuppression is believed to be a key factor; however, no immunosuppressive regimen has been identified to be more beneficial or less harmful. Donor age limitations, exclusion of moderately to severely steatotic livers and minimization of ischemic times could be a potential strategy to minimize the severity of HCV disease in transplanted subjects. After transplantation, antiviral therapy based on pegylated IFN alpha with or without ribavirin is associated with far less results than that reported for immunocompetent HCV-infected patients. New findings in the field of immunotherapy and genomic medicine applied to this context are promising.

© 2012 Baishideng. All rights reserved.

Key words: Hepatitis C; Liver transplantation; Recurrence; Immunosuppression; Treatment

INTRODUCTION

Chronic hepatitis C is the most common indication for liver transplantation (LT) in Western countries. It is recognized that recurrence of hepatitis C virus (HCV) infection after LT is immediate and universal, based on the presence of HCV-RNA in serum and liver. However, the recurrence of HCV disease requires protocol and/or clinically indicated liver biopsies that report both grade and stage of disease.

Despite early reports suggesting that recurrent HCV infection after LT was a relatively benign condition, numerous later studies have shown that histological progression of HCV liver disease is accelerated following LT. As a result, 30% of liver transplanted patients with HCV develop graft cirrhosis within 5 years. This rapidly progressing disease ultimately determines reduced graft and patient survival. At 5 and 10 years after LT, survival is 75% and 68% respectively, compared with 85% and 78% for other indications. Forman and co-authors, in the analysis of the United Network for Organ
United States. Many transplant centers have adopted a steroid-free regimen or have reduced their steroid use. Therefore, since the second half of the nineties, many studies have been published on the effects of immunosuppressive regimens on HCV recurrence and patient survival. The aim of this paper is to review the factors that may impact on recurrent HCV after LT and the current strategies to minimize the severity of recurrence and ameliorate its course.

**IMMUNOSUPPRESSION**

Immunosuppression is believed to be the principal factor in determining the severity of recurrent HCV liver disease, and thus, the poorer outcome of HCV patients after LT, in comparison with HCV immunocompetent subjects in the general population.

However, there is no consensus about the agent or regimen responsible for the severity of evolution of HCV recurrence. The First International Liver Transplantation Society Consensus Conference in 2003 stated that the optimal strategy is to achieve a balance between prevention of acute and chronic rejection while minimizing the potential negative effects of immunosuppression on recurrent hepatitis C.

Data available on the effect of the different immunosuppressive agents on HCV replication and/or progression of recurrent hepatitis C are limited by many factors, such as: (1) the retrospective nature of the studies; (2) the lack of HCV-RNA data and of routine protocol liver biopsies in the majority of the reports; and (3) the heterogeneity of immunosuppressive regimens. All these aspects prevent a clear determination of the specific effect of each individual drug on HCV disease recurrence.

**Steroids**

Steroids, including both the total steroid dose and, most markedly, steroid bolus treatment for rejection, have historically been associated with worse HCV outcomes. Therefore, since the second half of the nineties, many transplant centers have adopted a steroid-free regimen or rapid steroid tapers, reporting favorable results.

However, later studies have demonstrated a worsening of hepatitis C outcomes after LT during the era in which steroid and immunosuppressive minimization strategies were employed, even if the results of the studies may have been influenced by other changes occurring in the LT setting, such as increased donor age.

Recent data regarding the use of steroids for immunosuppression in HCV positive LT patients are controversial.

Klintmalm and co-authors, in a large (n = 312) randomized controlled study, did not find any differences in terms of recurrence of HCV and patient or graft survival in immunosuppressed subjects with or without steroid treatment after LT.

A meta-analysis of 19 randomized controlled trials (RCTs) on steroid avoidance after LT, conducted in 2008 by Segev and co-authors, evidenced that HCV recurrence was lower in patients not assuming steroids (RR = 0.90, P = 0.03). The results of this study are, however, limited by the heterogeneity of trials, the relatively small size of many RCTs and the short-term follow-up.

Also in regard to steroid use, some authors have suggested that rapid changes in the patients’ immunological status may lead to worse hepatitis C outcome, possibly by enhancing viral replication during the period of intense immunosuppression, with a destruction of HCV infected hepatocytes during the phase of immune reconstitution. Three studies, two retrospective and one prospective, supported this hypothesis, reporting improved outcome of recurrent hepatitis C when a slower steroid taper was adopted. However, in the prospective study, no differences were found in overall survival or death from recurrent hepatitis C. In LT practice, both steroid boluses for mild episodes of acute rejection as well as very rapid tapering are likely to be deleterious strategies in HCV patients and it seems wise to avoid these approaches.

**Calcineurin-inhibitor**

With regard to the impact of Calcineurin-inhibitor (CNI), many studies, mostly retrospective, have not found relevant differences between cyclosporine (CyA) and tacrolimus (Tac)-based immunosuppressive regimens in terms of HCV recurrent disease or survival.

The prospective studies comparing Tac to CyA have evaluated, in large part, other end-points, such as rejection rate and/or short-term survival, without addressing the problem of HCV recurrence. In a prospective randomized controlled study of 495 recipients with HCV infection, no difference was detected in the histological recurrence rate of hepatitis C between patients receiving CyA or Tac in the first year after LT.

In 2006, Berenguer and co-authors conducted a meta-analysis of 5 RCTs, comparing Tac and CyA after LT and with a minimum follow-up of 12 mo. The analysis, including a total of 366 transplant recipients, showed that...
Table 1 Outcome of hepatitis C virus liver transplanted patients treated with cyclosporine or tacrolimus-based immunosuppression in studies including protocol liver biopsy

| Ref.                  | Time of biopsy (yr) | CyA-based regimen | Tac-based regimen | P value |
|-----------------------|---------------------|-------------------|-------------------|---------|
| Carbone et al[42]     | At 1 and 5¹         | No hepatitis      | 12/109            | 0.1     |
|                       |                     | Mild chronic hepatitis | 59/109            |         |
|                       |                     | Moderate chronic hepatitis | 30/109            |         |
|                       |                     | Cirrhosis         | 8/109             |         |
| Testa et al[43]       | 1                   | Evidence of recurrence | 72/156            | 0.4     |
| Berenguer et al[44]   | 1                   | F0                | 16/44             | NS      |
|                       |                     | F1                | 16/44             |         |
|                       |                     | F3                | 8/44              |         |
|                       |                     | F4                | 4/44              |         |
| Berenguer et al[45]   | 1                   | F = 3-4           | 27/90             | 0.37    |
|                       |                     | F = 3-4           | 42/110            | 0.8     |

¹It is not clearly specified in the paper when liver biopsies have been performed. CyA: Cyclosporine; Tac: Tacrolimus; NS: Not significant.

The impact of the antimitabolites on HCV recurrence after LT remains an open issue. Many studies have shown an antiviral and antifibrotic effect of mycophenolate mofetil (MMF)[40-44]. Faola et al[43] reported decreased 3 month HCV-RNA levels after induction with MMF in HCV positive liver transplant recipients.

In 2005, Bahra et al[40] evidenced that patients treated with MMF and CNI taper presented a significantly de-celerated impairment of liver graft histology compared to a matched control group on CNI only, without any difference in terms of viral load. Similar findings have recently been reported by our group on a small population of HCV positive recipients switched from CNI to MMF compared with a control group of recipients remaining on CNI. The CNI group presented a significant increase of fibrosis with a yearly fibrosis progression rate of 0.33 ± 0.24 vs 0.05 ± 0.44 in the MMF group (P = 0.04)[46].

These data are in contrast with a previous report showing a significant impairment of liver histology after MMF treatment without tapering of CNIs[47].

MMF can be beneficial for liver inflammation and fibrosis because it allows CNI reduction and therefore a reduction of immunosuppression, without increasing the risk of acute rejection; however, a direct effect, mediated by the inhibition of lymphocyte proliferation through the block of the guanine nucleotides necessary for DNA synthesis, along with an antiviral effect, may also explain the decreased inflammatory activity and, therefore, the beneficial impact on fibrosis progression.

Furthermore, MMF, added to Tac and steroids, has been associated with an improved survival in patients with HCV compared to those treated with Tac and steroids alone, as shown in 2005 by the analysis of the Scientific Registry of Transplant Recipients database[48].

Regarding azathioprine, its impact on HCV recurrent disease has been recently evidenced by Mansou et al and co-authors who analyzed 103 recipients, randomized to Tac monotherapy (n = 54) or triple therapy with Tac, azathioprine and steroids (n = 49); those on triple therapy had a slower onset of histologically proven severe fibrosis and portal hypertension in comparison with those on monotherapy. The beneficial effect of the triple therapy in this study may be attributed to the long-term azathioprine therapy, as suggested by the authors[49].

Two large randomized trials comparing MMF to azathioprine in a maintenance immunosuppressive regimen showed no significant differences in either rates of recurrence of hepatitis C or outcomes in HCV infected patients in the study vs controls[47].

Other immunosuppressants
T-cell depleting therapies, such as Alemtuzumab (Campath) are very effective in the treatment of refractory acute rejection, although caution should be used in patients who are HCV positive[50,51]. Interleukin-2 receptor antibody-based therapy does not seem to be associated with a deleterious effect on HCV recurrence[52].
Complete weaning of immunosuppression

Some authors speculated that progression of HCV disease may be more related to excessive administration of immunosuppressant post LT, rather than the long-term effect of a specific immunosuppressive agent[57].

With this perspective, in our center we attempted the complete withdrawal of immunosuppression in thirty HCV recipients. Complete weaning was feasible only in eight (25%) patients. These subjects, however, exhibited a slower rate of fibrosis progression, a lower necroinflammatory score, improved liver tests and lower HCV-RNA levels compared to those who did not achieve sustained immunosuppression withdrawal[53]. While 6.5 years follow-up data showed a less marked impact of the immunosuppression free state on the progression of HCV disease, a reduction of IS-related morbidity and an increase of the quality of life was recorded[54].

EXTENDED CRITERIA DONORS

The rising demand for LT along with the shortage of organs is a critical issue in the liver transplant field. In order to expand the donor pool, living donors extended criteria donors (ECD), including older donors, fatty livers, longer ischemia time and donation after cardiac death (DCD), have been increasingly utilized. Grafts of reduced quality from ECD may show an increased sensitivity toward additional damaging events such as ischemia/reperfusion injury, acute rejection episodes or recurrent hepatitis C.

Donor age

Donor age is an established risk factor for severity of HCV recurrence and reduced graft and patient survival[55,56]. In 2005, the analysis of the US Scientific Registry of Transplant Recipients, including 3463 patients with hepatitis C, evidenced that donor age between 41 years and 50 years was associated with a 67% increase in the risk of graft loss; the risk increased to 86% for donors between 51 years and 60 years of age and was more than 2-fold greater when donors were older than 60 years[57]. Interestingly, Selzner et al[58] showed that younger HCV positive patients with older grafts had better long-term results when compared with older HCV positive recipients receiving older grafts. Ideally, HCV-infected transplant recipients should not receive organs from older donors; however, considering the vast number of HCV-infected patients awaiting LT, this may not be feasible for many programs.

Steatosis

Steatosis has been shown to accelerate the progression of HCV disease in immuno-competent patients; moreover, a strong association exists between the presence of donor steatosis and the development of primary nonfunction after LT[60]. Literature regarding the potential impact of steatosis on post-LT outcome in HCV recipients is scarce and no standard grading of steatosis is used; thus, no comparison is possible. Two recent studies have addressed this question and found that steatotic grafts do not have a negative impact on the progression of HCV recurrence and on patient survival in HCV positive recipients[59,60]. Different results were reported by Briceño and coworkers who evidenced that HCV recurrence was earlier and more frequent in recipients with moderate-severe steatosis. Therefore, the authors suggest that grafts with a steatosis > 30% should be avoided in HCV positive recipients[61]. Considering the conflicting results, no recommendation can be drawn in this context.

Ischemia time

Prolonged cold and warm ischemia times have also been identified as risk factors for more severe post-LT HCV infection[62].

Donors after cardiac death

The use of livers from DCD is a recovery technique based on cardiopulmonary rather than neurological criteria for death, and the warm ischemic time is typically prolonged. It is associated with a significantly higher risk of graft failure and development of biliary complications[64-67], although more recent studies have reported good clinical outcomes[68].

Two recent studies evaluated the impact of DCD livers on survival in HCV positive recipients. Yagei and coworkers evidenced a reduced 1 year and 5 year graft survival in the DCD group compared to the donation after brain death group (55% and 46% versus 85% and 78%, respectively; P < 0.0003)[69]; Tao and coworkers showed a reduced 1 and 5 year graft survival in the DCD group, although the difference is not significant (70% and 61% vs 82% and 74%, respectively, P = 0.24). However, the rates of severe HCV recurrence (re-transplantation or death due to recurrent hepatitis C and/or the development of stage 4/6 fibrosis or more within 2 years) were similar in the two groups[70].

The evidence is not sufficiently complete to advise against the use of DCD liver in this setting; additional studies with a large number of patients are required to fully determine how HCV positive patients can truly benefit from the use of DCD livers. According to experts, a donor graft biopsy is highly recommended when a DCD liver is used in an HCV positive recipient[71].

LIVING DONOR LIVER TRANSPLANTATION

Living donor LT (LDLT) is a further important strategy to increase the pool of organs available for patients awaiting LT. There are several theoretical advantages over deceased donor LT (DDLT), including reduced cold ischemia time, generally younger donor age, lack of steatosis and the ability to perform the transplant electively. Theoretically, these factors may positively affect graft outcome. However, controversy remains as to whether HCV recurs
with greater severity in LDLT and whether this negatively affects graft and patient survival.

Early reports suggested that HCV infection recurred with greater severity in recipients of LDLT compared with recipients of DDLT[73-75].

A more severe HCV recurrence in LDLT could be explained by: (1) human leukocyte antigen homology between donor and recipient[76]; (2) HCV replication in proliferating hepatocytes; (3) a greater relative immunosuppression[77] in particular; and (4) more biliary and vascular complications, thus enhancing fibrosis progression[78].

In 2007, the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL), involving different liver transplant centers in the USA and including 275 HCV patients, showed that graft survival rates for LDLT and DDLT were similar, once centers have sufficient experience with LDLT[79]. Moreover, the authors found no differences in terms of histological features or time to progression to Ishak stage 3 or more, at 1 year after transplant between the two groups. However, only 28% of the HCV positive population in this study received a liver biopsy at 1 year after transplantation. These findings were confirmed in other studies[80-82].

In 2008, Selzner and coauthors evidenced a slower fibrosis progression in LDLT recipients than in DDLT recipients (DDLT: 0.19 fibrosis stage/year vs LDLT: 0.11 fibrosis stage/year, P < 0.05), showing for the first time a possible beneficial impact of LDLT on HCV recurrence; the authors explained that this finding was likely due to younger donor age in LDLT recipients[83].

A strategy to improve the outcome of LDLT in HCV positive disease would be to treat HCV infection before LT, planning the optimal timing to initiate antiviral therapy; this is easier compared to DDLT since LDLT is a scheduled surgical procedure.

It is well known that the incidence of biliary complications (or vascular complications leading to biliary leaks or stenosis) can be reduced in experienced hands after the learning curve[84].

Some authors also suggest that an LDLT program should be preferentially started in individuals with alcoholic cirrhosis, cholestatic diseases or hepatitis B virus-related cirrhosis, in whom the graft will not unequivocally suffer cumulative injuries[85]. This latter point, however, has not been validated.

CYTOMEGALOVIRUS INFECTION

Cytomegalovirus (CMV) infection has been associated with an increased risk for severity of HCV recurrence. It is not clear whether this is correlated to the inherent immunosuppressive properties of the CMV itself or if CMV infection is only a surrogate marker for over-immunosuppression[86]. While CMV prophylaxis is largely used when needed in the transplant protocols, its impact on HCV recurrence is difficult to assess.

TREATMENT

Current approaches to the management of HCV recurrence after LT are represented by pre-transplant antiviral therapy, with the goal of preventing re-infection of the graft and post-transplant antiviral therapy, with the goal of eradicating recurrent infection, thus preventing recurrent disease and graft loss.

Hepatitis C therapy before LT

The primary goal of pre-transplant antiviral therapy is the achievement of an undetectable HCV RNA level prior to transplantation eliminating the risk of re-infection of the graft[87].

Antiviral treatment with a standard regimen of Pegylated-Interferon (Peg-IFN) and Ribavirin (RBV) for patients with compensated cirrhosis (Child Pugh Class A) is widely accepted and recommended by international practice guidelines[87,88]. On the other hand, antiviral treatment of patients with decompensated cirrhosis (Child class B or C) represents a far more problematic approach.

Everson and co-workers analyzed the largest cohort (n = 124) of HCV-candidates for LT (mean CPT score = 7.4; mean MELD score = 11) undergoing antiviral treatment with interferon (peginterferon and nonpegylated forms) and RBV with a low-accelerating dose regimen, reporting an on-treatment virological response rate of 46% and a SVR rate of 24% (50% in genotype 2 or 3 and 13% in genotype 1). Seventy-one percent failed to achieve full doses and 13% discontinued early. Recurrent HCV infection was prevented in all patients achieving SVR[89]. Similar rates were reported in another experience with a smaller population[90].

The achievement of “on-treatment virological response” represents a secondary goal in pre-transplant treatment, as it has been shown to significantly reduce the risk of graft reinfection[91]. Forns and co-workers treated 30 patients (50% Child-Pugh class A), starting the treatment when the expected time to LT was around 4 mo; the rationale was that most virological responders achieve HCV-RNA undetectability by week 12 and this could be sufficient to prevent infection after removing the main source of virus. 9 (30%) of 30 patients achieved on-treatment virological response, which persisted in 6 (20%) after transplantation.

Pre-transplant treatment should be limited to patients with mild liver decompensation as those with advanced decompensation (Child-Class B to C or MELD >18) have a high risk for severe complications[92,93].

Close monitoring during treatment is suggested and the therapy should be administered in liver clinics affiliated with liver transplant programs. In order to manage severe cases of liver decompensation, patients should ideally already be on the list for transplantation before initiation of antiviral therapy[94].

Good candidates for pre-transplant therapy would be naïve patients or prior relapers of standard IFN and RBV treatment, as the chances for an on-treatment virological response before transplant are relevant in these groups. Furthermore, good candidates may be patients with living donors, with a predictable timing of transplantation, patients with compensated cirrhosis and those
with hepatocellular carcinoma, who typically have lower MELD scores.

Recent data suggest that thrombopoietin receptor agonists, such as eltrombopag, may be a useful tool for improving pretreatment platelet counts in HCV cirrhotic patients who would otherwise be ineligible for therapy[92].

**Treatment of established hepatitis C recurrence**

The most widely used strategy involves initiating antiviral therapy once the consequences of the recurrence of HCV infection are detected on liver biopsy. The goal of therapy is to achieve viral eradication and this is associated with a survival benefit[92].

Treatment duration after transplantation is generally 12 mo, regardless of HCV genotype. The SVR rate is far less than that reported for immunocompetent HCV-infected patients. The mean overall SVR rate in the studies considering the efficacy of Pegylated-IFN and RBV was 30.2%, with a range of 8%-50%, 28.7% for genotype 1, with a range of 12.5%-40% and 71%-100% in patients with genotype 2 (Table 2). Secondary end-points of the treatment to be considered are the biochemical response (around 60% of cases) and histological improvement, in terms of reduction of inflammation, although this seems to be confined only to patients achieving a SVR.

Tolerance is worse compared with nontransplant patients with chronic hepatitis, with a percentage rate of dose reduction and discontinuation of 68 and 25, respectively. Usually, RBV is initiated at a dose of 400-600 mg daily and then increased slowly according to patient tolerability. The use of growth factors is common due to the high prevalence of hematological side effects[94,96-108].

The same SVR on treatment predictor used in the non-transplant setting, such as early virological response (EVR), treatment adherence, baseline viremia and HCV genotype, seem to also be reliable after LT.

Recently, Berenguer et al[50], in a retrospective analysis of 107 recipients treated with Peg-IFN and RBV, evidenced a strong relationship between donor age and outcome of antiviral therapy, as treatment failure was significantly more frequent in recipients of grafts from older donors. Authors recommend that antiviral therapy should be started in the early stages of disease in recipients of grafts from old donors, in whom the risk of progressive recurrent disease is higher and the chances of antiviral success are lower.

IFN-therapy after transplant is historically associated with a potential risk of acute cellular rejection (ACR), due to the immunomodulatory properties of IFN. The reported incidence of ACR ranges from 0 to 25%, with a mean incidence of 12%. The frequency and severity of ACR is typically not greater than that reported in patients

---

**Table 2 Results of studies on treatment with Pegylated interferon and Ribavirin of recurrent hepatitis C after liver transplant**

| Ref.               | Yr | Type of Study | Time since LT (mo) | n | Genotype (%) | Antiviral Therapy | SVR (%) | Discontinuation (%) |
|--------------------|----|---------------|--------------------|---|--------------|-------------------|---------|---------------------|
| Rodriguez-Luna et al[90] | 2004 | Prospective, uncontrolled | 4.2 | 19 | 63 | Peg-IFN 0.5-1.5 μg/kg/wk + RBV 400-1000 mg daily x 48 wk | 26 | 49 |
| Neff et al[91] | 2004 | Retrospective, uncontrolled | 23.5 | 57 | 98 | Peg-IFN 1.5 μg/kg/wk + RBV 400-600 mg daily x 48 wk | 14 | 32 |
| Dumontier et al[92] | 2004 | Prospective, uncontrolled | 28 | 20 | 80 | Peg-IFN 0.5-1.0 μg/kg/wk + RBV 400-1200 mg daily x 48 wk | 45 | 20 |
| Castells et al[93] | 2005 | Prospective, controlled | 3.8 | 24 | 100 | Peg-IFN 1.5 μg/kg/wk + RBV 400-800 mg daily x 48 wk | 35 | 13 |
| Berenguer et al[94] | 2006 | Retrospective, uncontrolled | 16.6 | 36 | 89 | IFN and RBV/Peg-IFN and RBV | 18 | 40 |
| Oton et al[95] | 2006 | Prospective, uncontrolled | 63.3 | 55 | 91 | Peg-IFN 180 μg/1.5 μg/kg/wk + RBV 11 mg/kg/d x 48 wk | 24 | 7 |
| Mukherjee et al[96] | 2006 | Retrospective, uncontrolled | 16 | 32 | 75 | Peg-IFN 180 μg + RBV 1000-1200 mg daily x 48 wk | 34 | 15 |
| Mukherjee et al[97] | 2006 | Prospective, uncontrolled | 20 | 39 | 79 | Peg-IFN 1.5 μg/kg/wk + RBV 800 mg daily x 6-12 mo | 33 | 43 |
| Fernandez et al[98] | 2006 | Prospective, uncontrolled | 32 | 47 | 93 | Peg-IFN 1.5 μg/kg/wk + RBV 800-1000 mg daily x 48 wk | 23 | 21 |
| Neumann et al[99] | 2006 | Prospective, uncontrolled | 38 | 25 | 80 | Peg-IFN 1.0 μg/kg/wk + RBV 600 mg daily x 48 wk | 36 | 4 |
| Picciotto et al[100] | 2007 | Prospective, uncontrolled | 25 | 61 | 87 | Peg-IFN 1 μg/kg/wk RBV 600-800 mg daily x 6-12 mo | 28 | 15 |
| Angelico et al[101] | 2007 | Prospective, uncontrolled | 48 | 21 | 81 | Peg-IFN 180 μg + RBV 200-800 mg daily x 48 wk | 33 | 55 |
| Carrión et al[102] | 2007 | Prospective, controlled | 14.5 | 54 | 92 | Peg-IFN 1.5 μg/kg/wk + RBV 400-1200 mg daily x 48 wk | 33 | 39 |
| Sharma et al[103] | 2007 | Retrospective, uncontrolled | 16 | 35 | 77 | Peg-IFN 90-180 μg/0.5-1.5 μg/kg/wk + RBV 800 mg daily x 48 wk | 37 | 74 |
| Zimmermann et al[104] | 2007 | Prospective, uncontrolled | 9.4 | 26 | 88 | Peg-IFN 180 μg/kg/wk + RBV 400-1000 mg daily x 48 wk | 19 | 11 |

LT: Liver transplant; IFN: Interferon; Peg: Pegylated; RBV: Ribavirin; SVR: Sustained virological response.
with recurrence of HCV infection who are not receiving antiviral therapy.\textsuperscript{[109]}

A higher risk of developing alloimmune hepatitis is reported, typically after HCV RNA clearance (approximately 5% of cases).\textsuperscript{[109]}

**Preemptive antiviral therapy and early therapy**

In the preemptive strategy, the treatment is started within the first few weeks post-transplantation, when HCV-RNA values are low, before peaking at 3 mo to 4 mo post-transplantation. Candidates for preemptive therapy are patients without significant post-transplant complications, such as cytopenias, renal dysfunction and infections.

There are only two RCTs reporting the safety and efficacy of peginterferon alfa-2a in the early postoperative period\textsuperscript{[110]} but the sample size is small. In the “prophylaxis trial”, the treatment was initiated within 3 wk after LT and achieved a SVR of 8% (n = 2). In the “treatment trial”, where the treatment was started 6 mo post-LT, the SVR was 12% (n = 5). The rate of discontinuation of therapy was 31%.

Non-randomized preemptive trials reported rates of SVR ranging from 5% to 33% in genotype 1 patients and from 14% to 100% in genotype 2/3 patients. The reported rate of treatment discontinuation ranged from 0% to 57% and dose reductions (ranging from 28% to 85%) were required more frequently for interferon rather than for ribavirin.\textsuperscript{[111-114]}

Interestingly, Kuo \textit{et al}.\textsuperscript{[115]} analyzing a cohort of recipients receiving preemptive therapy, evidenced a long-term histological benefit in those receiving preemptive therapy, even if non-responders; fibrosis score \( \geq 2 \) at 48 mo post-LT was reported in 22% patients undergoing preemptive therapy versus 49% of those that did not receive preemptive therapy (\( P = 0.08 \)).

Another strategy consists of starting the antiviral therapy at the first clinical manifestation of “acute” recurrent HCV, usually occurring within the first 6 mo after transplantation (“early therapy”). SVR rates range from 13% to 35% in genotypes 1 and the tolerability seems to be improved (discontinuation 0%-13%). However, early preemptive therapy is not suitable for all transplant recipients.\textsuperscript{[107,108,117]}

Considering its low tolerability profile and the dismal results in terms of SVR, preemptive and early antiviral therapies are not largely recommended for the treatment of HCV recurrence, except in patients at high risk for progressive disease.

**Adoptive immunotherapy**

The immunosuppressive regimen currently used after LT reduces the adaptive immune components but effectively maintains the innate components of cellular immunity.\textsuperscript{[118-120]} The enhancement of the natural killer cellular response that plays a pivotal role in innate immunity may be a promising immunotherapeutic approach, also in the prevention of HCV recurrence post-LT.\textsuperscript{[121]}

Ohira \textit{et al}.\textsuperscript{[122]} report an interesting immunotherapeutic approach for preventing post-transplant HCV recurrence, based on adoptive transfer of interleukin 2 (IL-2)/anti-CD3 monoclonal antibody (OKT3)-treated liver allograft-derived lymphocyte pools enriched in natural killer and natural killer T cells.

This was a phase 1 clinical trial in which 14 patients were treated with liver allograft-derived lymphocytes. During the first months after LT, HCV RNA levels were significantly lower on average in the treated recipients than in the controls. HCV RNA became undetectable after immunotherapy in two treated patients 4 wk after LT but in none of the controls. In one of the treated patients, HCV RNA was still undetectable 20 mo after LT, whereas HCV infection recurred 2 mo after transplantation in the second one.

Although the results were incomplete or transient, this study provides a new approach to the problem and opens new perspectives in the prevention of HCV infection after LT.

**Prophylactic therapy**

There is evidence suggesting a possible role for hepatitis C immune globulin in the prevention of recurrent HCV infection after LT. The prevalence of HCV recurrence after LT was lower in those who received HBIG than in the controls. HCV RNA became undetectable after immunotherapy in two treated patients 4 wk after LT but in none of the controls. In one of the treated patients, HCV RNA was still undetectable 20 mo after LT, whereas HCV infection recurred 2 mo after transplantation in the second one.

| IMPACT OF GENOMIC MEDICINE ON HCV RECURRENCE |

From 2009, single nucleotide polymorphisms (SNPs) near the \( IL28B \) gene were identified by genome-wide association studies and were associated with SVR or non-response to treatment with PEG-IFN-\( \alpha \) and RBV alone or in combination with protease-inhibitors.\textsuperscript{[124,125]} It was estimated that the genotype of these SNPs accounts for approximately 15% of the inter-individual differences in SVR rates after standard treatment in HCV genotype 1 patients.\textsuperscript{[134]}

Most recently, a number of studies have analyzed the role of genetic variants of \( IL28B \) in the severity of HCV recurrence and antiviral treatment response.

Eurich \textit{et al}.\textsuperscript{[135]} evaluated only the role of the recipient genotype and reported that IL-28b polymorphism seems to influence the degree of graft inflammation at the biochemical and histological levels. The G-allele has been proposed as a marker for graft inflammation and a pre-
dictor for unfavorable antiviral therapy outcome in HCV-infected LT-population.

Lange et al.\[34\], who also investigated the donor genotype, evidenced that response to antiviral therapy was strongly associated with the donor IL28B major genotype (T/T) but only weakly with the recipient’s IL28B genotype.\[35\]

In contrast, other studies have reported that both recipient and donor genotypes seemed to influence the response to Peg-IFN + RBV.\[17\]-[19]\.

Furthermore, it has been shown that an unfavorable IL28B genotype was associated with more rapid fibrosis, but not with decreased survival.\[19\]

These findings may open new interesting scenarios in the field of recurrence of HCV disease after LT, such as changes in the graft allocation system by determining the IL28B genotype of potential donors; this may identify the optimal graft/recipient matching in order to improve the sensitivity to antiviral therapy for HCV infection post-transplantation and therefore improve outcomes.

**CONCLUSION**

Management of recurrent HCV disease is one of the most challenging problems in the transplant hepatology. Overall excess immunosuppression seems to have an impact on HCV disease progression, although no beneficial immunosuppressive drug has been identified so far. Optimizing the donor selection, with donor age limitations, the exclusion of moderately to severely steatotic livers and the reduction of ischemic times, could be a potential strategy to minimize the severity of HCV recurrence and improve the outcome of HCV positive recipients. Pre-transplant antiviral therapy is limited by low tolerability, low SVR and is indicated in a limited population of transplant candidates.

Post-transplant combination antiviral therapy in those with evidence of recurrent disease is the mainstay of management and has a beneficial effect on virological, biochemical and histological responses in patients with HCV infection post-LT.

In the long term, specifically targeted antiviral therapies that block the replication of HCV, such as HCV protease and polymerase inhibitors, associated with Peg-IFN and RBV, may achieve higher rates of SVR becoming the standard of care.

Future research focusing on the role of prophylactic therapy and immunotherapy are needed in this important patient population.

**REFERENCES**

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. *Gastroenterology* 2002; 122: 889-896
2. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, Combs C, Fennessy S, Roberts JP, Ascher NL. Recurrent and acquired hepatitis C viral infection in liver transplant recipi-ents. *Gastroenterology* 1992; 103: 317-322
3. König V, Bauditz J, Lobeck H, Lüsebrink R, Neuhaus P, Blumhardt G, Bechstein WO, Neuhaus R, Steffen R, Hopf U. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. *Hepatology* 1992; 16: 1137-1143
4. Shah G, Demetris AJ, Gavalter JS, Lewis JH, Todo S, Starzl TE, Van Thiel DH. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. *Gastroenterology* 1992; 103: 323-329
5. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL. HCV-related fibrosis progression following liver transplantation: increase in recent years. *J Hepatol* 2000; 32: 673-684
6. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the nonomothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). *J Hepatol* 2006; 45: 127-145
7. Berenguer M, Prieto M, San Juan F, Rayón JM, Martínez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. *Hepatology* 2002; 36: 202-210
8. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. *Transplantation* 2004; 77: 226-231
9. Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. *Am J Transplant* 2006; 6: 1398-1406
10. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. *Liver Transpl* 2003; 9: S1-S9
11. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detwe K, Hoornagel J. Predictors of patient and graft survival following liver transplantation for hepatitis C. *Hepatology* 1998; 28: 823-830
12. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. *Liver Transpl Surg* 1999; 5: S107-S114
13. Lladó L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, Torras J, García-Gil A, González-Pinto I, Castellote J, Ballel C, Fabregat J, Rafecas A. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. *J Hepatol* 2006; 44: 710-716
14. Eason JD, Nair S, Cohen AJ, Blazeck JL, Loss GE. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. *Transplantation* 2003; 75: 1396-1399
15. Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, Shrestha R, Stegall M. Early steroid withdrawal in liver transplantation is safe and beneficial. *Liver Transpl Surg* 1999; 5: 548-557
16. Belli LS, Alberti AB, Vangeli M, Airoldi A, Pinzello G. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. *Liver Transpl* 2003; 9: 201-202
17. Klinfelter GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. *Liver Transpl* 2007; 13: 1521-1531
18. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA, Cameron AM, Maley WR. Steroid avoidance in liver transplantation: meta-analysis and
meta-regression of randomized trials. *Liver Transpl* 2008; 14: 512-525

19 Verna EC, Brown RS. Hepatitis C virus and liver transplantation. *Clin Liver Dis* 2006; 10: 919-940

20 Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D’Errico A, Furlini G, Bellucci R, Roda E, Cavallari A. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. *Liver Transpl* 2002; 8: 884-888

21 Berenguer M, Aguileria V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722

22 Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, D’Errico A, Guido M, Merenda R, Neri D, Zanello M, Giannini FM, Grazi GL, Cillo U, Pinna AD. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007; 47: 793-798

23 Bilbao I, Pou L, Allende E, Lázaro JL, Charco R, Hidalgo E, Margarit C. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. *Transplant Proc* 2001; 33: 2124-2126

24 Paik SW, Tan HP, Klein AS, Boillot JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci 2002; 47: 450-455

25 Sánchez-Fueyo A, Restrepo JC, Quintó L, Bruguera M, Grande I, Sánchez-Tapia JM, Rodés J, Rimola A. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. *Transplantation* 2002; 73: 56-63

26 Berenguer M, Aguileria V, Prieto M, Carrasco D, Rayón M, San Juan F, Landavere C, Mir J, Berenguer J. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? *Liver Transplant* 2003; 9: 1152-1158

27 Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. *Liver Transpl* 2003; 9: 796-804

28 Neumann UP, Berg T, Bahra M, Seebofer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836

29 Rimola A, Londoño MC, Guevara G, Bruguera M, Nasava M, Forns X, García-Retortillo M, García-Valdecasas JC, Rodés J. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686-691

30 Bahr MJ, Beckermann JG, Rifai K, Gehrmann L, Roseneau J, Klemmpnauer J, Strassburg CP, Manss MP. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. *Transplant Proc* 2005; 37: 1703-1704

31 Lucey MR, Abdelmalek MF, Gagliardi R, Granger D, Holt C, Kain I, Klintmalm G, Langnas A, Shetty K, Tzakis A, Woodle ES. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. *Ann Transplant* 2005; 5: 1111-1119

32 A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. *N Engl J Med* 1994; 331: 1110-1115

33 Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. *Lancet* 1994; 344: 423-428

34 Levy G, Villamil F, Samuel D, Sanjua F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G. Results of lis2, a multicenter, randomized study comparing cyclo-

sporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. *Transplantation* 2004; 77: 1632-1638

35 Lewy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantissi G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. *Liver Transpl* 2006; 12: 1464-1472

36 Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. *Liver Transpl* 2007; 13: 21-29

37 Berenguer M, Aguileria V, San Juan F, Benlloch S, Rubín A, López-Andujar R, Moya A, Pareja E, Montalva E, Yago M, de Juan M, Mir J, Prieto M. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. *Transplantation* 2010; 90: 1204-1209

38 Crabbé R, Vuagniaux G, Dumont JM, Nicolas-Métral V, Marfurt J, Novaroli L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. *Expert Opin Investig Drugs* 2009; 18: 211-220

39 Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. *Am J Transplant* 2009; 9: 1707-1713

40 Ying C, De Clercq E, Neys J. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. *Antiviral Res* 2000; 48: 117-124

41 Neys J, De Clercq E. The anti-herpesvirus activity of (1’5,S,2’R)-[1’,2’-bis(hydroxymethyl)-cyclcoprop-1’-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. *Antiviral Res* 2001; 49: 121-127

42 Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neys J, De Clercq E, Yap SH. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. *J Viral Hepat* 1999; 6: 229-236

43 Roos N, Poualhohn N, Farge D, Madelaine I, Mauriel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. *J Pharmacol Exp Ther* 2007; 321: 585-589

44 Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W. Antifibrotic actions of mycophenolic acid. *Clin Transplant* 2006; 20 Suppl 17: 25-29

45 Faola CGT, Netto G, Christensen LL, Rakela J, Thomas M. Lower incidence of early HCV-RNA levels and HCV recurrence post liver transplantation in patients induced with mycophenolate mofetil: A high-dose benefit. *Am J Transplant* 2002; 2 Suppl: 323A

46 Bahra M, Neumann U, Jacob D, Puhl G, Klupp J, Langrehr JM, Berg T, Neuhaus P. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. *Am J Transplant* 2005; 5: 406-411

47 Jain A, Kashyap R, Demetris AJ, Eghtesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. *Liver Transpl* 2002; 8: 40-46

48 Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake MR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. *Liver Transpl* 2005; 11: 750-759

49 Manousou P, Samonakis D, Cholongitas E, Patch D, O’Beirne J, Dillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. *Liver Transpl* 2009; 15: 1783-1791

50 Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M,
Gentili F, Risalde B, Rubin A, Cañada R, Palau A, Rayón JM. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 736-746

Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, Marsh W, Gayowski T, Demetris AJ, Gray EA, Flynn B, Zeevi A, Murase N, Starzl TE. Use of altemutumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2008; 78: 966-971

Filipponi F, Salizzoni M, Grazi G, Pisati R, Ferrara R. Study of simucluc-based, steroid-free immunosuppressive regimen in HCV+ de novo liver transplant patients: preliminary results. Transplant Proc 2001; 33: 3211-3212

Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, Lionetti R, Anselmo A, Totti L, Angelico M. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2004; 40: 702-709

Orlando G, Manzia T, Baiocchi L, Sánchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transplant Immunol 2008; 20: 43-47

Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-252

Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, Rosser BG, Satyanarayana R, Grewal HP, Hewitt WR, Harmsos DM, Crook JE, Steers JL, Dickson RC. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92

Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549-557

Selzner N, Kashki A, Selzner N, McCluskey S, Greig PD, Cattral MS, Levy GA, Lilly L, Renner EL, Terapondos G, Adcock LE, Grant DR. McGillivray ID. Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. Liver Transplant 2009; 15: 1288-1295

Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, Stewart G, McCaughan G. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transplant 2003; 9: 500-505

Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, Fox IJ, Sudan DL, Shaw BW, Langnas AN. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Transplant 2007; 13: 758-763

Burra P, Lorenzi M, Russo FP, Germini G, Galligioni A, Zenzolo M, Cillo U, Zanus G, Fagioli S, Rugge M. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transplant 2009; 15: 619-628

Briceno J, Ciria R, Pleguezuelo M, de la Mata M, Montané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Ruiñán S, López-Cilleró P. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transplant 2009; 15: 37-48

Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C post-transplant: early preservation injury may predict poor outcome. Liver Transplant 2006; 12: 134-139

Mateo R, Cho Y, Singh G, Stapfer M, Donovan J, Kahn J, Fong TL, Sher L, Jabbour N, Assawd S, Selby RR, Genyk Y. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant 2006; 6: 791-796

de Vera ME, Lopez-Solís R, Dvorčuk I, Campos S, Morris W, Demetris AJ, Fontes P, Marsh JW. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant 2009; 9: 773-781

Foley DP, Fernandez LA, Leveson G, Chin LT, Krüger N, Cooper JT, Shames BD, Becker YT, Odoctor JS, Knecht SJ, Sollinger HW, Kalayoglu M, D’Alessandro AM. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg 2005; 242: 724-731

Chan EY, Olson LC, Kisthard JA, Perkins JD, Bakhavat- salam R, Halldorsson JB, Reyes JD, Larson AM, Levy AE. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transplant 2008; 14: 604-610

Grewal HP, Willingham DL, Nguyen J, Hewitt WR, Taner BC, Cornell D, Rosser BG, Keaveny AP, Aranda-Michel J, Satyanarayana R, Harmsos D, Dickson RC, Kramer DJ, Hughes CB. Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. Liver Transplant 2009; 15: 1028-1035

Yamamoto S, Wilczek HE, Duraj FF, Groth CG, Ericzon BG. Liver transplantation with grafts from controlled donors after cardiac death: a 20-year follow-up at a single center. Am J Transplant 2010; 10: 602-611

Yagci G, Fernandez LA, Knecht SJ, D’Alessandro AM, Chin LT, Musat AI, Lucey MR, Said A, Pirsch JD, Leveson G, Kalayoglu M. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc 2008; 40: 219-223

Tao R, Ruppert K, Cruz RJ, Malik SM, Shaikh O, Ahmad J, DiMartini A, Humar A, Fontes PA, de Vera ME. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transplant 2010; 16: 1288-1295

Berenguer M. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transplant 2008; 14 Suppl 2: S45-S50

Gaglio PJ, Malireddy S, Levitt BS, Lapointe-Rudow D, Lefkowitch J, Kinkhabwala M, Russo MW, Emond JC, Brown RS. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transplant 2003; 9: 1028-1035

García-Retortillo M, Forns X, Llovet JM, Navasa M, Felu A, Massaguer A, Bruguera M, Fuster J, García-Valdecasas JC, Rimola A. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699-707

Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transplant 2004; 10: 1263-1268

Everson GT, Trotter J. Role of adult living donor liver transplantation in patients with hepatitis C. Liver Transplant 2005; 9: 564-568

Honda M, Kaneko S, Matsushita E, Kobayashi K, Abell GA, Lemon SM. Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Gastroenterology 2000; 118: 152-162

Yersiz H, Renz JF, Farmer DG, Hisatke GM, McDiamid SV, Busultil RW. One hundred in situ split-liver transplantations: a single-center experience. Ann Surg 2003; 238: S46-S50, discussion S46-S57

Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS, Everson GT, Reddy KR, Fair JH, Kulik LM, Pruitt TL, Seef LB. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transplant 2007; 13: 122-129

Humar A, Horn K, Kalis A, Blessing B, Payne WD, Lake J. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005; 5: 399-405

Guo I, Orrego M, Rodriguez-Luna H, Balan V, Byrne T,
How to prevent and manage biliary complications in living donor liver transplantation. *Liver Transpl* 2005; 43: 22-27

Carrío JA, Forns X. Living donor liver transplantation and hepatitis C: lessons from the learning curve? *Liver Transpl* 2007; 13: 18-20

Eversen GT. Should we treat patients with chronic hepatitis C on the waiting list? *J Hepatol* 2005; 42: 456-462

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009; 49: 1335-1374

McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Gore D, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. *J Gastroenterol Hepatol* 2007; 22: 615-633

Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, Bombardieri G, Andruilli A. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus infection and decompensated cirrhosis: a controlled study. *J Hepatol* 2007; 46: 206-212

Forns X, Navasa M, Rodés J. Treatment of HCV infection in patients with advanced cirrhosis. *Hepatology* 2004; 40: 498

Crippin JS, McCashland T, Terrail N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. *Liver Transpl* 2002; 8: 350-355

McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH. Ertomabop for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* 2007; 357: 2227-2236

Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. *Am J Transplant* 2008; 8: 679-687

Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calcio F, Cuomo O, Ascione A. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. *J Hepatol* 2007; 47: 459-465

Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremer WK, Rosen CB, Heimbach JK, Charlton MR. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. *Am J Transplant* 2008; 8: 2426-2433

Ross AS, Bhan AK, Pascual M, Thim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver-transplant recurrent hepatitis C. *Clin Transplant* 2004; 18: 166-173

Dumortier J, Scocacez JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. *J Hepatol* 2004; 40: 669-674

Rodríguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. *Transplantation* 2004; 77: 190-194

Neff GW, Montalbanco M, O’Brien CB, Nishida S, Saadkar K, Bejarano PA, Khaled AS, Ruiz P, Slapak-Green G, Lee M, Nery J, De Medina M, Tzakis A, Schiff ER. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alpha2-b and ribavirin therapy. *Transplantation* 2004; 78: 1303-1307

Tonitto P, Fabris C, Fumo E, Apollonio L, Caldato M, Avellini C, Minisini R, Piris M. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. *J Gastroenterol Hepatol* 2005; 20: 577-582

Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. *Can J Gastroenterol* 2005; 19: 359-365

Berenguer M, Palau A, Fernandez A, Benlloch S, Aguiler A, Prieto M, Rayón JM, Berenguer J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. *Liver Transpl* 2006; 12: 1067-1076

Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garson S, Moreno A, Boulosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. *Am J Transplant* 2006; 6: 2348-2355

Mukherjee S, Lyden E. Impact of pegylated interferon alpha-2b and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. *Liver Int* 2006; 26: 529-535

Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbrares C, Moreno E, Solis-Herruzo JA. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. *Liver Transpl* 2006; 12: 1805-1812

Neumann U, Puhl G, Bahra M, Berg T, Langreh JM, Neuhau RS, Neuhau P. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2b plus ribavirin. *Transplantation* 2006; 82: 43-47

Castells L, Vargas V, Allende I, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. *J Hepatol* 2005; 43: 53-59

Angelicco M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, Merli M, Strazzaboso M, Tisoni G. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. *J Hepatol* 2007; 46: 1009-1017

Chalasani N, Navaneethan S, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riel Y, Martin P, Teperman L, Jiao J, Lopez-Talaver JC. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. *Hepatology* 2005; 41: 289-298

Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. *J Hepatol* 2011; 55: 207-217
119 Granier C, Feinstone SM, Cosset FL, Purcell RH. Neutraliz
Yu MY H. Hepatitis C (HCV) and hepatitis B (HBV) in patients with
Feray C allograft-derived lymphocytes induces anti-HCV activity
Chayama K, Ohdan H. Adoptive immunotherapy with liver
Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T,
Ohira M 1712-1719 mita Y, Maehara Y. IL-12 gene therapy is an effective thera
ing living-related liver transplantation.
Hirata M fer and in vivo expansion of human haploidentical NK cells
dorf DJ, Okazaki IJ, McGlave PB. Successful adoptive trans
sition after liver transplantation.
on alpha-2a plus ribavirin in the early phase of HCV reinfec
MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
Zimmermann T Antivir Ther 2006; 11: 1061-1070
127 Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, 
Kanzler S, Greif-Higer G, Barreiros AP, Sprinz MF, Wörns 
MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M. 
Efficacy of an escalating dose regimen of pegylated interfer-
on alpha-2a plus ribavirin in the early phase of HCV reinfe-
cion after liver transplantation. Transplant Int 2007; 20: 583-590
128 Miller JS, Soignet Y, Fanoskalsits-Mortari A, McNeary 
Sa, Yun GH, Fautsch SK, McKenna L, Le C, Defor TE, Burns 
LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weis-
dorf DJ, Okazaki JJ, McGlave PB. Successful adoptive trans-
fer and in vivo expansion of human haploidentical NK cells 
in patients with cancer. Blood 2005; 105: 305I-3057
119 Hirata M, Kita Y, Saito N, Nishimura M, Ito M, Mizuta 
K, Tanaka H, Haririya H, Kawarasaki H, Hashizume K, 
Makuzhi M. Increase in natural killer cell activity following 
living-related liver transplantation. Transplant Int 1998; 11 
Suppl 1: S185-S189
120 Harada N, Shimada M, Okano S, Suehiro T, Sosejima Y, 
To- mita Y, Maehara Y. IL-12 gene therapy is an effective therapeu-
tic strategy for hepatocellular carcinoma in immunosup-
pRESSED mice. Immunol 2004; 173: 6635-6644
121 Ohira M, Ohdan H, Mitsuta H, Ishiyama K, Tanaka Y, Igar-
rashi Y, Asahara T. Adoptive transfer of TRAIL-expressing 
natural killer cells prevents recurrence of hepatocellular car-
cinoma after partial hepatectomy. Transplantation 2006; 82 
7172-1719
122 Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y. 
Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, 
Chayama K, Ohdan H. Adoptive immunotherapy with liver 
allograft-derived lymphocytes induces anti-HCV activity after 
liver transplantation in humans and humanized mice. J Clin 
Invest 2009; 119: 3262-3265
123 Feray C, Gágou M, Samuel D, Thiery V, Bernauj J, Bismuth 
H. Hepatitis C (HCV) and hepatitis B (HBV) in patients with 
fulfant hepatitis. Hepatology 1991; 14: 130A
124 Yu MY, Bartosch B, Zhang P, Guo ZP, Renzi PM, Shen LM, 
Granier C, Feinstone SM, Cosset FL, Purcell RH. Neutraliz-
ing antibodies to hepatitis C virus (HCV) in immune globu-
llins derived from anti-HCV-positive plasma. Proc Natl Acad 
Sci U S A 2004; 101: 7705-7710
125 Kawczynski K, Alter MJ, Tankersley DL, Beach M, Rob-
erston BH, Lambert S, Kuo G, Spellbrin JE, Meeks E, Sinha 
S, Carson DA. Effect of immune globulin on the prevention of 
experimental hepatitis C virus infection. J Infect Dis 1996; 173: 822-828
126 Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, 
Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ, Guann 
JW. A randomized, open-label study to evaluate the safety and 
pharmacokinetics of human hepatitis C immune globulin 
(Civacir) in liver transplant recipients. Liver Transplant 2005; 11: 941-949
127 Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, 
Tur-Kaspa R, Eren R, Dagan S, Graham N, Williams PV, 
Andrews J. Monoclonal antibody HCV-AbXTL68 in patients 
undergoing liver transplantation for HCV: results of a phase 2 
randomized study. Liver Transpl 2006; 12: 1381-1389
128 Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban 
TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, 
McHutchison JG, Goldstein DB. Genetic variation in IL28B 
predicts hepatitis C treatment-induced viral clearance. 
Nature 2009; 461: 399-401
129 Rallón NJ, Naggie S, Benito JM, Medrano J, Restrepo C, 
Goldstein D, Shianna KV, Vips E, Thompson A, McHutchi-
son J, Soriano V. Association of a single nucleotide polymor-
phism near the interleukin-28 gene with response to hepa-
titis C therapy in HIV/hepatitis C virus-coinfected patients. 
AIDS 2010; 24: F23-F29
130 Rauch A, Kutalik Z, Descombes P, Cai T, Di Julio J, Mueller T, 
Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo 
S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, 
Hirschel B, Mainwaring R, Moradpour D, Mühlhaupt B, Wite-
tek A, Beckmann JS, Berg T, Bergmann S, Negro F, Teleni 
A, Bochud PY. Genetic variation in IL28B is associated with 
chronic hepatitis C and treatment failure: a genome-wide as-
sociation study. Gastroenterology 2010; 138: 1338-1345
131 Suppiah V, Moldovan M, Ahlsten G, Berg T, Weltman A, 
Abate ML, Bassendine M, Spengler U, Dore CJ, Powell E, 
Riordan S, Sheridan D, Smeddle A, Fragomelli V, Müller T, 
Bahlö M, Stewart CJ, Booth DR, George J. IL28B is associated 
with response to chronic hepatitis C interferon-alpha and ribavirin 
therapy. Nat Genet 2009; 41: 1100-1104
132 Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura 
K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, 
Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, 
Sakai A, Hiasa Y, Nishiguchi S, Koihe A, Sakaida I, Imamura 
M, Ito K, Yano K, Masaki N, Sugachi F, Isumi N, Tokunaga 
K, Mizokami K. Genome-wide association of IL28B with 
response to pegylated interferon-alpha and ribavirin therapy 
for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109
133 Akuta N, Suzuki F, Hirakawa M, Kawarasa Y, Yatsuji H, 
Sekazi H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, 
Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Ku-
mado H. Amino acid substitution in hepatitis C virus core 
region and genetic variation near the interleukin 28B gene 
predict viral response to telaprevir with peginterferon and 
ribavirin. Hepatology 2010; 52: 421-429
134 Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, 
Shianna KV, Urban T, Adhal NH, Jacobson IM, Esteban 
R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler 
S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, 
Hirschel B, Mainwaring R, Moradpour D, Mühlhaupt B, Wit-
eck A, Beckmann JS, Berg T, Bergmann S, Negro F, Teleni 
A, Bochud PY. Genetic variation in IL28B is associated with 
chronic hepatitis C and treatment failure: a genome-wide as-
sociation study. Gastroenterology 2010; 138: 1338-1345
135 McHutchison JG, Goldstein DB. Genetic variation in IL28B 
predicts hepatitis C treatment-induced viral clearance. 
J Infect Dis 2004; 190: 770-7710
Carbone M et al. Prevention of hepatitis C recurrence after liver transplantation

136 Lange CM, Moradpour D, Doehring A, Lehr HA, Mullhaupt B, Bibert S, Bochud PY, Antonio AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, Lotsch J, Zeuzem S, Hofmann WP. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-327.

137 Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139:1577-1585.

138 Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, Carrión JA, Martinez SM, Sanchez-Tapias JM, Martorell J, Navasa M, Forns X. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-1057.

139 Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.

140 Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.

141 Sharma P, Marrero JA, Fontana RJ, Greenspan JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-1108.

142 Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.

143 Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, Brooks BK, Levy MF, Gonwa TA, Klintmalm GB. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553-561.

144 Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12: 762-767.

S-Editor Wang JL  L-Editor Roemmele A  E-Editor Zhang DN